Repligen
Supplies filtration, chromatography, analytics, and protein technologies for biologics manufacturers and CDMOs.
$181.00
After-hours close+4.79 (+2.72%)
At close$176.21(−3.20%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 132.36%Insiders 0.68%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 56.44M · Float 53.37M · 94.6% free float
Institutions13F, as of Jun 30, 2026
494 holders · 74.70M shares · 101 new positions · 279 increased · 139 reduced · 62 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.38M | 9.54% | −608.1K | Aug 7, 2026 |
| FMR LLC | 3.33M | 5.89% | +439.9K | Aug 13, 2026 |
| United Capital Financial Advisers, LLC | 2.79M | 4.94% | +16.7K | Aug 17, 2026 |
| Vanguard Capital Management LLC | 2.41M | 4.27% | +14.7K | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 2.31M | 4.10% | +7.7K | Aug 13, 2026 |
| Maverick Capital Ltd | 1.98M | 3.52% | +465.7K | Aug 14, 2026 |
| State Street Corp | 1.80M | 3.19% | +23.2K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.75M | 3.10% | −3.13M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 9.30% | 5.20M | 13G | Apr 24, 2025 ↗ |
| T. Rowe Price Associates, Inc. | 8.20% | 4.60M | 13G | Feb 17, 2026 ↗ |
| FMR LLC | 5.10% | 2.89M | 13G | Feb 5, 2026 ↗ |
| Vanguard Capital Management | 5.00% | 2.83M | 13G | Jul 31, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Karen A. Dawes | director | 92.8K | 0.16% | May 18, 2026 |
| Anthony Hunt | director | 89.1K | 0.16% | Mar 3, 2026 |
| Olivier Loeillot | director, officer: Chief Executive Officer | 54.2K | 0.10% | Aug 21, 2026 |
| Glenn P. Muir | director | 40.1K | 0.07% | May 18, 2026 |
| James Bylund | officer: Chief Operating Officer | 25.4K | 0.05% | Mar 23, 2026 |
| Ralf Kuriyel | officer: Senior VP, R&D | 20.1K | 0.04% | Mar 23, 2026 |
| Jason K. Garland | officer: CFO | 18.8K | 0.03% | Jul 17, 2026 |
| Martin D. Madaus | director | 8.4K | 0.01% | May 18, 2026 |
| Brian Robb Douglass | officer: CHIEF PRODUCT OFFICER | 8.0K | 0.01% | May 8, 2026 |
| Manner Carrie Eglinton | director | 5.5K | 0.01% | May 18, 2026 |
4 ten-percent owners hold 3.15M shares by Form 4, outside the officers-and-directors figure above · 21 people have not refiled in the last 18 months (1.83M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 20, 2026 | Olivier Loeillotdirector, officer: Chief Executive Officer | Sale | 5,426 | $180.00 | 54,246 |
| Jul 16, 2026 | Jason K. Garlandofficer: CFO | Sale | 530 | $150.00 | 18,829 |
| Jun 25, 2026 | Jason K. Garlandofficer: CFO | Sale | 733 | $145.00 | 19,359 |
| Apr 21, 2026 | Olivier Loeillotdirector, officer: Chief Executive Officer | Sale | 3,832 | $140.00 | 54,246 |
| Dec 17, 2025 | Karen A. Dawesdirector | Sale | 275 | $161.00 | 91,821 |
| Nov 25, 2025 | Olivier Loeillotdirector, officer: Chief Executive Officer | Sale | 7,041 | $170.00 | 35,898 |
| Nov 18, 2025 | James Bylundofficer: Chief Operating Officer | Sale | 2,191 | $151.21 | 21,520 |
| Nov 13, 2025 | Anthony Huntdirector | Sale · 7 lots | 20,000 | $154.61 | 80,743 |
| Nov 12, 2025 | Anthony Huntdirector | Sale · 5 lots | 25,000 | $156.88 | 100,743 |
| Sep 10, 2025 | Anthony Huntdirector | Sale · 6 lots | 29,111 | $120.52 | 100,743 |
CongressHouse and Senate disclosures
Not reported.